Key Highlights

  • First-half Revenue rose 6.7% to £954.3m, with underlying operating profit up 41.7% to £48.6m.
  • EBITDA increased 16.4% to £96.7m, with the Margin widening to 10.1%.
  • Net Debt rose to £671.3m at 30 June 2026, up from £575.0m at the end of 2025.
  • Management guided full-year 2026 EBITDA to around £162m and flagged that roughly £6m of the gain came from a temporary supply-disruption benefit.
  • The Dividend remains suspended until net debt falls below 2.5x EBITDA.

Synthomer (LSE:SYNT), the speciality chemicals maker behind coatings, adhesives and nitrile latex, delivered a punchy set of first-half figures on 4 August 2026: revenue up 6.7% to £954.3m, EBITDA up 16.4% to £96.7m and underlying operating profit up 41.7% to £48.6m. Management even nudged full-year 2026 guidance to slightly ahead of market expectations. Yet the shares gave a jittery, contradictory response, with several sessions of heavy selling that dragged the stock back toward the 98p region even as other reports flagged an initial double-digit pop. Net debt climbed to £671.3m over the half, dividends remain suspended, and investors are fixated on whether fragile second-half margins can survive rising input costs. The market reaction says as much about Synthomer's Leverage and cyclicality as it does about a genuinely improved trading picture.

What happened?

On 4 August 2026 Synthomer published interim results for the six months to 30 June 2026 and used the release to raise its full-year outlook, telling investors it now expects 2026 to land slightly ahead of market forecasts.

The operational story was clearly improving. Revenue rose 6.7% to £954.3m, helped by 2.3% Volume growth and a 2.8% price and mix contribution. EBITDA jumped 16.4% to £96.7m, the EBITDA margin widened 80 basis points to 10.1%, and underlying operating profit surged 41.7% to £48.6m, the figure that anchors the supplied headline.

The share-price response, however, was anything but clean. Some market reports flagged an initial rally of well over 10% on results day, while others described the stock sliding as much as 14% toward 98.4p as investors dug into the detail. That whipsaw reaction, rather than the headline profit growth, became the story: a strong first half met by scepticism about whether the momentum can last.

Underlying the numbers is Synthomer's continued pivot toward speciality chemistry. Speciality products now account for roughly 55% of revenue, with management targeting 70% over time as it tries to move away from volatile, commoditised end-markets such as nitrile latex.

The numbers investors need to know

The headline profitability metrics were genuinely strong, but the Balance Sheet is where the caution creeps in.

Net debt rose to £671.3m at 30 June 2026, up sharply from £575.0m at the end of 2025, reflecting seasonal working-capital swings and higher raw-material costs. Management guided year-end leverage to a range of roughly 4.0x to 4.35x EBITDA, still elevated for a cyclical chemicals business. Underlying Profit before tax improved to £13.2m from £4.2m a year earlier, though on a reported basis the loss before tax widened to £27.7m.

  • Revenue: £954.3m, up 6.7% year on year (constant-currency growth of 5.1%).
  • Underlying operating profit: £48.6m, up 41.7%.
  • EBITDA: £96.7m, up 16.4%; margin 10.1% (+80bps).
  • Underlying profit before tax: £13.2m versus £4.2m.
  • Net debt: £671.3m at 30 June, up from £575.0m at end-2025.
  • Full-year 2026 EBITDA guidance: around £162m, versus £137m in 2025, implying roughly 18% growth.
  • Dividend: still suspended until net debt falls below 2.5x EBITDA.

Why the market may be concerned

The core worry is sustainability. Management acknowledged that part of the first-half strength was temporary. Roughly £6m of the EBITDA gain came from a Supply disruption benefit, with only about £8m attributable to recurring strategic initiatives. In plain terms, some of the profit uplift was a windfall from customer stockpiling and Asian supply outages that may not repeat.

At the same time, cost pressure is building. Reports pointed to significant increases in raw-material and energy costs since the flare-up of conflict involving Iran, while bulk chemical prices — nitrile latex in particular — have started to soften as Chinese availability improves. For a Business that runs on the spread between input costs and selling prices, rising costs and weakening prices are a dangerous combination for second-half margins.

Then there is leverage. With net debt at £671.3m and year-end leverage guided at up to 4.35x, Synthomer has limited room for error. Dividends remain suspended, and until the balance sheet deleverages meaningfully, income investors have little reason to step in. The fact that guidance was only nudged to slightly ahead, rather than materially upgraded, may also have disappointed those hoping the strong first half would translate into a bolder full-year statement.

Why bulls may see an opportunity

For the more optimistic, the first half is evidence that the multi-year turnaround is finally showing up in the numbers. Underlying operating profit rising more than 40%, EBITDA up double digits and a margin expanding for the fourth consecutive year are not trivial achievements in a soft chemicals market.

The speciality pivot is the strategic heart of the bull case. With speciality products already at around 55% of revenue and a 70% target, Synthomer is deliberately reducing its exposure to the commoditised swings that have hurt it before. Gross margin has expanded roughly 600 basis points over four years, suggesting the self-help programme is structural rather than cyclical.

Cash generation is turning as well, with management guiding to positive free Cash Flow in the second half and improved leverage by year-end. If that plays out, the deleveraging narrative — and eventually the resumption of dividends — comes back into view. For a stock trading at a fraction of its former value, even modest re-rating potential is significant should the company demonstrate that the first half was not a one-off.

What happens next?

The decisive test is the second half of 2026. Investors will watch closely whether the temporary tailwinds fade faster than the recurring self-help gains build, and whether raw-material Inflation squeezes the spread business. The full-year results, due in early 2027, will confirm whether the roughly £162m EBITDA guidance holds.

Balance-sheet progress is the other swing factor. Delivery of promised second-half free cash flow, and a year-end leverage figure at the better end of the 4.0x-4.35x range, would materially strengthen sentiment. Any slippage on either front would likely reignite concerns about the debt load.

Beyond that, the market will look for evidence that the speciality mix keeps shifting toward the 70% target and that pricing discipline holds as Chinese nitrile supply returns. Given the stock's leverage and cyclicality, expect continued Volatility around each trading update.

Outlook

Synthomer (LSE:SYNT)'s first half delivered exactly the kind of profit growth bulls have been waiting for — underlying operating profit up 41.7%, EBITDA up 16.4% and an upgraded, if cautious, outlook. The problem is that the market is looking through the headline. With net debt up to £671.3m, leverage still around 4x, dividends suspended and management openly flagging that part of the uplift was temporary, investors are pricing the risk that second-half margins compress as input costs rise and nitrile prices soften. The result was a volatile, contradictory share reaction rather than a clean re-rating. The turnaround is real, but so is the leverage. Until Synthomer proves the recurring gains outweigh the windfalls and the debt starts falling, the shares are likely to stay a battleground between improving fundamentals and a fragile balance sheet.